KUMAMOTO University

R

研究実績RESEARCH ACHIEVEMENTS

  1. Takenaka K, Minami T, Yoshihashi Y, Hirata S, Kimura Y, Kono H.

    Decrease in MPO-ANCA after administration of benralizumab in eosinophilic granulomatosis with polyangiitis.

    Allergol Int.2019 Oct;68(4):539-540. doi: 10.1016/j.alit.2019.04.006. Epub 2019 May 9. PMID: 31080020

  2. Nakata H, Maeda K, Das D, Chang SB, Matsuda K, Rao KV, Harada S, Yoshimura K, Ghosh AK, Mitsuya H.

    Activity and structural analysis of GRL-117C: a novel small molecule CCR5 inhibitor active against R5-tropic HIV-1s.

    Sci Rep. 2019 Mar 18;9(1):4828. doi: 10.1038/s41598-019-41080-w. PMID: 30886166; PMCID: PMC6423129

    https://pubmed.ncbi.nlm.nih.gov/30886166/

     

     

  3. Ishikawa M, Iriyama N, Tokuhira M, Takaku T, Sato E, Sugimoto K J, Nakazato T, Fujita H, Kimura Y, Fujioka I, Komatsu N, Asou N, Kizaki M, Hatta Y, Kawaguchi T.

    Potential role for secondgeneration tyrosine kinase inhibitors in patients with chronic myeloid leukemia harboring additional clonal chromosome abnormalities: A retrospective CML Cooperative Study Group analysis.

    Oncol Rep.2019 Dec;42(6):2836-2843. doi: 10.3892/or.2019.7339. Epub 2019 Sep 27. PMID: 31578586

  4. Ikebe E, Matsuoka S, Tanaka A, Yonemura Y, Fujii Y, Ohsaka A, Okazaki H, Kitazawa J, Ohtani S, Nakayama T, Momose S, Miwa I, Taira R, Yoyota K, Kino S, Kato H, Hamaguchi I.

    Reduction in adverse transfusion reactions with increased use of washed platelet concentrates in Japan- A retrospective multicenter study.

    Transfusion and Apheresis Science .2019 Apr;58(2):162-168.  PMID: 30670326

    https://pubmed.ncbi.nlm.nih.gov/30670326/

     

  5. Shirayama R, Takedani H, Chikasawa Y, Ishiguro A, Ishimura M, Isobe K, Uchiba M, Ogata Y, Kakuda H, Kusuhara K, Shirahata A.

    Perioperative safety and haematostatic efficacy of a new bypassing agent pd-FVIIa/FX (Byclot) in haemophilia patients with high-responding type inhibitors.

    Blood Coagul Fibrinolysis.2019 Dec;30(8):385-392. doi: 10.1097/MBC.0000000000000851. PMID: 31738288

  6. Iida S, Ishida T, Murakami H, Ozaki S, Abe M, Hata H, Shimazaki C.

    JSH practical guidelines for hematological malignancies, 2018: III. Myeloma-1. Multiple myeloma (MM)

    International Journal of Hematolog. 2019 May;109(5):509-538. doi: 10.1007/s12185-019-02636-8. Epub 2019 Apr 4. PMID: 30949913

  7. Nagafuji K, Matsumura I, Shimose T, Kawaguchi T, Kuroda J, Nakamae H, Miyamoto T, Kadowaki N, Ishikawa J, Imamura Y, Yamazaki H, Akashi K, Kanakura Y.

    Cessation of nilotinib in patients with chronic myelogenous leukemia who have maintained deep molecular responses for 2 years: a multicenter phase 2 trial, stop nilotinib (NILSt).

    Int J Hematol .2019 Dec;110(6):675-682. doi: 10.1007/s12185-019-02736-5. PMID: 31538327

CONTACT US

C

  • 患者様へ

    外来診療の方は外来予約センターより
    ご予約をお願いいたします。
    外来予約センター

  • 学生・研修医・医療関係者の方へ

    TEL
    096-373-5156
    FAX
    096-373-5158
    Mail
    nikyo@kumamoto-u.ac.jp
Copyright 2019 KUMAMOTO University HRI All Rights Reserved.